Scienture Aims to Showcase Revenue Growth and Pipeline Progress at…

Event summary

Scienture Holdings, Inc. (NASDAQ: SCNX) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026.
Management will highlight the commercial progress of Arbli™ and the Q3 2026 launch of REZENOPY™.
Q2 2026 revenue increased approximately 510% sequentially to $344,000, with a gross margin of approximately 98%.
The company aims to achieve profitability in 2027.

The big picture

Scienture is entering a critical phase in its evolution, with the commercial success of Arbli™ and the launch of REZENOPY™ positioning the company for meaningful revenue growth. The pharmaceutical sector is increasingly focused on specialty products that address unmet market needs, and Scienture's strategy aligns with this trend. The company's ability to achieve profitability in 2027 will be a key indicator of its long-term viability in a competitive market.

What we're watching

Revenue Growth: How the continued ramp of Arbli™ and the launch of REZENOPY™ will affect Scienture's top-line revenue growth in the second half of 2026 and into 2027.
Profitability: Whether Scienture can sustain its strong gross margins and disciplined operating expense structure to achieve profitability in 2027.
Pipeline Progress: The pace at which Scienture advances its pipeline of differentiated drug candidates to create additional opportunities for future product development and commercialization.